BPC-157

What Is BPC-157?

BPC-157 (Body Protection Compound 157, also referenced in published literature as PL-14736) is a synthetic 15-amino-acid pentadecapeptide derived from a partial sequence identified within human gastric juice protein.

The sequence is described in the published literature as exhibiting relative resistance to enzymatic degradation compared to many short-chain peptides, a property attributed in research literature to its specific amino acid composition and sequence architecture.

In published research literature, BPC-157 is studied primarily in the context of nitric oxide pathway modulation, angiogenic signaling, and gastrointestinal mucosal biology, with additional research on growth hormone receptor interactions. Human clinical evidence for BPC-157 remains limited; the published research base is primarily preclinical.

BPC-157 in Plain Language

A non-technical overview of what BPC-157 is, what researchers have studied it for, what the early evidence suggests, and what cannot be claimed about it. For research and educational purposes only.

At a glance

BPC-157 is a small lab-made peptide based on a natural compound first found in stomach fluid. Scientists are studying it as a possible accelerator of the body’s own healing, especially how it might help the body grow new blood vessels and recover from injuries to tendons, ligaments, muscle, and the gut lining.

Most of what’s known so far comes from animal and laboratory studies, and researchers are looking at whether those healing signals work consistently across different kinds of tissue. The compound sold here is a research chemical, not a drug or supplement, and is not for human or animal use.

What it is

BPC-157 is a synthetic peptide made of 15 amino acids. The name stands for “Body Protection Compound 157.” It is based on a partial sequence of a larger protein originally identified in human gastric juice. In the published clinical trial literature it has also been listed under the development code PL-14736.

Researchers commonly study BPC-157 in laboratory settings related to blood-vessel signaling, gastrointestinal lining biology, and connective-tissue repair models such as tendons and ligaments. Most of what is known about it comes from animal studies and cell-based experiments rather than from large human trials.

Research areas being investigated

• Tissue repair research: Studied in animal models for how it may influence cellular signals involved in wound and connective-tissue repair.
• Tendon and ligament research: Examined in rat models of tendon detachment and tendon-to-bone healing.
• Gastrointestinal research: Investigated in animal models of stomach ulcer, colitis, and gut barrier injury.
• Inflammation research: Looked at for how it may affect inflammatory response pathways in laboratory models.
• Blood-vessel and nitric-oxide research: Studied in cell and animal experiments related to nitric oxide (NO) signaling, endothelial function, and angiogenesis (new blood-vessel formation).
• Nerve-related research: Explored in some animal models involving nerve injury and pain signaling, though this body of evidence is smaller and more preliminary.

What the research suggests so far

Animal / preclinical findings. The largest body of published evidence on BPC-157 comes from rodent (mostly rat) studies. In these studies, researchers have reported observations consistent with faster healing in models of skin wounds, gastric ulcers, colitis, tendon detachment, ligament transection, ischemia/reperfusion injury, and intestinal anastomosis.

These findings are commonly described in published research as involving the nitric-oxide pathway and angiogenic signaling. They do not, on their own, demonstrate that BPC-157 produces the same effects in humans.

Cell / lab findings. In cell-culture experiments, published research has described BPC-157 as influencing endothelial nitric oxide synthase (eNOS) activity, vascular endothelial growth factor receptor 2 (VEGFR2) expression, and certain growth-factor signaling pathways. These mechanistic studies help researchers form hypotheses about how BPC-157 might act in tissue, but they are several steps removed from clinical outcomes.

Human findings. Human evidence for BPC-157 is limited. The most cited human work is an early-phase clinical program (Pliva, Croatia) that evaluated the closely related agent PL-14736 for safety, tolerability, and pharmacokinetics in healthy volunteers and explored its potential in inflammatory bowel disease.

Published reports describe an acceptable short-term safety profile in those small early-phase studies. There are no large, published Phase III randomized controlled trials demonstrating efficacy for any condition, and BPC-157 is not approved by the FDA, EMA, or other major regulators for any use.

Limitations of the evidence. Most of the published BPC-157 literature comes from a small number of research groups, much of it in rodent models. Long-term human safety data, large-scale efficacy trials, standardized dosing studies, and independent replication across many laboratories are all lacking.

Reviewers in the recent peer-reviewed literature have specifically called out the need for more rigorous, independently replicated human studies before any therapeutic conclusions can be drawn.

Research relevance

BPC-157 is most often discussed in research involving tissue-repair signaling, gastrointestinal mucosal biology, tendon and ligament injury models, vascular and nitric-oxide pathways, and inflammation models. Most published findings are preclinical, so it should not be presented as a proven treatment for any condition.

Its scientific interest lies in its potential use as a research tool for studying tissue-repair and vascular biology in the laboratory.

What cannot be claimed about BPC-157

• It cannot be claimed to treat, cure, heal, or repair any human or animal condition.
• It cannot be claimed to repair tendons, ligaments, joints, muscles, or nerves in humans.
• It cannot be claimed to treat ulcers, inflammatory bowel disease, leaky gut, or any digestive condition.
• It cannot be claimed to reduce pain, accelerate recovery from surgery, or improve athletic performance.
• It cannot be claimed to be safe or effective for human or veterinary use.
• It cannot be claimed to be approved by the FDA or any other regulatory authority.

Summary

BPC-157 (Body Protection Compound 157, also known as PL-14736) is a synthetic 15-amino-acid peptide derived from a sequence found in human gastric juice protein. It is studied in laboratory and animal research related to tissue-repair signaling, gastrointestinal lining biology, tendon and ligament injury models, and the nitric-oxide and angiogenesis pathways. Published evidence comes mainly from rodent and cell-culture experiments; human evidence is limited to small early-phase studies of the related agent PL-14736.

BPC-157 is not approved by the FDA or any other regulatory authority and is sold here strictly as a research-use-only chemical for laboratory investigation. It is not intended for human consumption, medical use, or veterinary use.

Short version

BPC-157 is a synthetic 15-amino-acid peptide most often studied in animal and cell-based research related to tissue repair, gut lining biology, and blood-vessel signaling. Human evidence is limited and it is not approved for any medical use. Sold for research and laboratory use only.

Source notes

• Jelińska J, et al. BPC-157 and Its Novel Hybrid Analogs as Inhibitors of Acetylcholinesterase. International journal of molecular sciences, 2026. (PubMed PMID: 42278509.)
• Sikiric P. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des, 2011, preclinical literature review. (PubMed PMID: 21548867.)
• Sikiric P, et al. Pentadecapeptide BPC 157, in clinical trials as a therapy for inflammatory bowel disease (PL-14736), is effective in the healing of colocutaneous fistulas in rats. J Pharmacol Sci, animal study. (PubMed PMID: 18818478.)
• Krivic A, et al. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157. J Orthop Res, 2006, animal study. (PubMed PMID: 16583442.)
• Vukojevic J, et al. Stable gastric pentadecapeptide BPC 157 in the treatment of colitis and ischemia and reperfusion in rats. World J Gastroenterol, 2017, animal study. (PMC5752708.)
• Deek SA, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. 2024, peer-reviewed narrative review. (PMC12446177.)
• Multifunctionality and Possible Medical Application of the BPC 157 Peptide, Literature and Patent Review. Pharmaceuticals (MDPI), 2025, review article.
• Ruenzi M, Stolte M, Veljaca M, Oreskovic K, Peterson J. PL-14736 (BPC-157) Phase II in mildly to moderately active ulcerative colitis, small early-phase human safety / pharmacokinetic data on the related agent PL-14736 (Pliva, Croatia), referenced in subsequent peer-reviewed reviews.

Source types: entries 1, 5, 6 are review articles; entries 2, 3, 4 are animal / preclinical studies; entry 7 references early-phase human safety / pharmacokinetic data on the related agent PL-14736.

Reminder. BioChain USA sells BPC-157 strictly as a research-use-only chemical for qualified laboratory and educational use. It is not intended for human consumption, medical treatment, veterinary treatment, diagnosis, prevention, or cure of disease.

Certificate of Analysis (COA)

• COA provided where available for the specific batch shipped.
• The batch COA is the authoritative reference for analytical methods, purity data, and lot-specific testing for that shipment.
• COA information is batch-specific and is not interchangeable between lots.

Frequently Asked Questions